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The mitotic protein polo-like kinase 4 (PLK4) plays a critical role in
centrosome duplication for cell division. By using immunofluores-
cence, we confirm that PLK4 is localized to centrosomes. In addi-
tion, we find that phospho-PLK4 (pPLK4) is cleaved and distributed
to kinetochores (metaphase and anaphase), spindle midzone/
cleavage furrow (anaphase and telophase), and midbody (cytoki-
nesis) during cell division in immortalized epithelial cells as well as
breast, ovarian, and colorectal cancer cells. The distribution of
pPLK4 midzone/cleavage furrow and midbody positions pPLK4 to
play a functional role in cytokinesis. Indeed, we found that inhibi-
tion of PLK4 kinase activity with a small-molecule inhibitor, CFI-
400945, prevents translocation to the spindle midzone/cleavage
furrow and prevents cellular abscission, leading to the generation
of cells with polyploidy, increased numbers of duplicated centro-
somes, and vulnerability to anaphase or mitotic catastrophe. The
regulatory role of PLK4 in cytokinesis makes it a potential target
for therapeutic intervention in appropriately selected cancers.
polo-like kinase 4 | cell cycle regulation | cytokinesis |
centrosome | midbody
The use of targeted cancer therapeutics that inhibit specificmolecular alterations to which some cancers are “addicted”
(1) has become a reality (2–4). Development of such therapies
has led to substantial progress in cancer treatments for specific
patient subgroups whose cancers contain these molecular alter-
ations. However, the current spectrum of adult malignancies with
novel therapeutic “targets” remains limited while the mainstay for
cancer treatment continues to be cytotoxic chemotherapy. Most
nonspecific chemotherapeutic agents are predominantly antimi-
totic drugs frequently prescribed in a “one-size-fits-all” fashion
based on the histology and extent of disease dissemination. A
great deal is now known about the network of mitotic serine/
threonine kinases that regulate the process of cell division, and
there are growing opportunities to bring more focused approaches
to the disruption of cell division, particularly in aneuploid cancer
cells. The requirements of segregating complex genomes of an-
euploid malignant cells into viable daughter cells produces vul-
nerability that could be exploited to therapeutic advantage.
A number of mitotic kinases are critically important in regu-
lating specific portions of the cell cycle. These include members
of the polo-like kinase (PLK) family, the cyclin-dependent kinase
(CDK) family, the aurora family, and the “never in mitosis A”
(NIMA) family, as well as those kinases implicated in mitotic
checkpoints (Bub1, BubR1, and TTK/Esk/Mps1), mitotic exit,
and cytokinesis. Accumulating evidence suggests that PLK4 is
not only an important cell-cycle regulatory protein but is also a
potential therapeutic target. Expression-array analyses identified
PLK4 as one of 16 serine-threonine kinases associated with poor
prognosis in breast cancer patients (5). PLK4 was also identified
as a therapeutic target for cancer by using high-throughput screens
that involve genome-wide small inhibitory RNA (siRNA) viability
analyses of multiple human cancer cell lines in which PLK4 de-
pletion significantly decreased viability in 8 of 21 cancer cell lines
tested and had only a limited effect on normal immortalized cell
lines (6, 7). In addition, the Broad Institute DepMap Web site
shows 497 of 517 cancer cell lines to be dependent on PLK4 by
using CRISPR-Cas9 methods (https://depmap.org/portal/gene/
PLK4?tab=overview) (8). Furthermore, PLK4 mRNA levels are
increased in human tumor specimens relative to paired normal
tissue, and these elevated levels correlate with poor survival (9).
Finally, an inhibitor of PLK4 kinase activity, CFI-400945, has been
shown to inhibit lung cancer growth in mice (9).
PLK4 functions at the intersection of mitotic and DNA
damage pathways (10), and aberrant expression is associated
with centriole increases and centrosome dysfunction (11, 12).
This may affect control of cell division and play a role in genomic
instability. An increase in centrosome number is frequently ob-
served in aneuploid cancers, in which it is proposed to play a
causal role in genome instability and tumor development as well
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as in tumor progression and aggressiveness (13). PLK4 is found on
human chromosome 4q28, a region that frequently undergoes loss in
hepatocellular carcinoma (14). Although full deletion of PLK4 leads
to embryonic lethality (15), PLK4+/− heterozygous mice are viable
but have ∼15 times greater probability of developing spontaneous
liver and lung cancers than PLK4+/+ homozygous littermates (16).
Members of the PLK family (PLK1–5) have an amino-termi-
nal serine/threonine kinase domain and two to three carboxyl-
terminal polo-boxes (PBs) that interact with other proteins.
PLK4 is unique among the PLK family and shares only limited
homology with other family members (17, 18). Other family
members have two PBs, whereas PLK4 has one C-terminal PB and
two cryptic PBs (CPBs) that function as PBs without a linker
region to facilitate PLK4 homodimerization and autophosphor-
ylation (19). The PLK4 cryptic PBs bind the centrosome proteins
(CEPs) CEP152 and CEP192 that direct intact PLK4 to this or-
ganelle. Other critical domains of PLK4 are composed of proline
(P), aspartate (D), glutamate (E), serine (S), and threonine (T)
amino acid residues with a uniquely abundant distribution (i.e.,
PEST domains) (20). These conserved PEST domains have been
demonstrated to serve as constitutive or conditional proteolytic
signaling sequences and function to regulate enzymatic protein
cleavage activities (21). Currently, PLK4 is recognized as having
an essential role in centriole duplication but not in regulating
cytokinesis (7, 11, 17, 18, 20, 22–26).
Because expression array analyses identified PLK4 as a serine-
threonine kinase associated with a poor prognosis in breast (5) and
lung (9) cancer patients and because PLK4 was identified as a
therapeutic target for cancer by using high-throughput screens (6, 7)
coupled with the established role of PLK4 in centrosome duplica-
tion and, therefore, regulation of cell division, we investigated the
role of PLK4 in cell cycle regulation and as a potential new target
for therapy with an anti-PLK4 kinase inhibitor, CFI-400945 (27–29).
Results
Localization of Phospho-PLK4 to Centrosomes. It is generally ac-
cepted that turnover of PLK4 kinase is strictly controlled to
prevent aberrant centriole increase or “amplification” (30). This
turnover is achieved by an autoregulatory mechanism in which
PLK4 homodimers are autophosphorylated at residues in a
downstream regulatory element located carboxyl-terminal to its
catalytic kinase domain (amino acids 285 and 289). Phosphory-
lated PLK4 is reported to be recognized by the SCF (S phase
kinase-associated protein 1–cullin–F-box) complex, ubiquiti-
nated, and targeted to the proteasome for degradation (18, 22,
30). Although PLK4 is reported to be restricted to the centro-
some (7, 17, 18, 22), the subcellular distribution of autophos-
phorylated PLK4 has not been characterized. We therefore
developed a phosphospecific antibody to the serine 305 residue
of PLK4, located within the first of three PLK4 PEST domains,
to track the localization of this form of PLK4. Similar to pub-
lished reports, antibodies recognizing the C-terminal PB domain
were localized to centrosomes of human ovarian (Fig. 1), breast,
and colorectal cancer cell lines throughout the cell cycle (7, 17,
18, 22, 30); however, the phospho-serine305-PLK4–specific an-
tibody also localized to kinetochores (metaphase and anaphase),
the central spindle midzone or the cleavage furrow (anaphase
and telophase), and midbody (cytokinesis) depending on cell-
cycle phase (Fig. 2). Similar results were obtained by using a
second phospho-S305-PLK4 antibody (14299).
Cleavage of Phospho-PLK4 and Localization to Kinetochores, Midzone/
Cleavage Furrow, and Midbody During M-Phase. Western immuno-
blot analyses using antibodies to an epitope centered on cysteine
458 (as detailed later) showed that PLK4 displayed the expected
electrophoretic mobility of a 97-kDa protein (Fig. 3 and SI Ap-
pendix, Fig. S1). In contrast, the major protein recognized by anti–
phospho-PLK4 (serine305) displayed a mobility of a 50–60-kDa
protein in breast, ovarian, and colorectal cancer cell lines, pre-
sumably because of protein cleavage rather than degradation of
the entire PLK4 molecule (Fig. 3 and SI Appendix, Fig. S1).
To confirm the specificity of our antibodies for two anti-
PLK4 antibodies and our phospho-serine305-PLK4 antibody, we
used various approaches. The first approach used competition studies
with different PLK4 peptides or recombinant protein, as described in
Materials and Methods, and these peptides succeeded in quenching
the immunofluorescence staining observed with each antibody.
The second approach, used to confirm the specificity of a com-
mercially available anti-PLK4 antibody recognizing an epitope
centered on cysteine 458 and our anti–phospho-PLK4 Ab#3, in-
volved siRNA directed to PLK4 in HCT-116 human colorectal
cancer cells, OVCAR3 human ovarian cancer cells, and
CAL51 human breast cancer cells to inhibit expression of PLK4 and
demonstrate that localization with our anti–phospho-PLK4 antibody
was specifically dependent on expression of PLK4. In each of these
cell lines, we found a greater than 90% suppression of PLK4
mRNA, a greater than 90% suppression of full-length PLK4 (de-
tected by a PLK4 antibody detecting a central PLK4 epitope sur-
rounding cysteine 458), and a greater than 90% suppression of
phospho-PLK4 detected with our anti–phospho-PLK4 antibody in
the centrosomes or in the midbodies (SI Appendix, Fig. S2).
The third approach, also to confirm specificity of our anti–
phospho-PLK4 antibody Ab#3, used lysates from OV90 ovar-
ian cancer cells and NCI-H716 colorectal cancer cells for affinity
chromatography with cross-linked anti–phospho-serine305-PLK4
antibody to separate antibody-bound and associated proteins
from other proteins in the lysate. The proteins bound by the
column were released and separately collected. The collected
proteins were separated by polyacrylamide gel electrophoresis
(PAGE) and identified by silver staining of the gel. One silver-
stained band of ∼50–60 kDa, corresponding to a similarly sized
band recognized in a parallel Western immunoblot, was de-
tected. This band was excised for mass spectrometry (MS) amino
acid sequence analyses. The sequence analyses yielded a single
peptide sequence (LKMPHEKHYTLCGTPN) that corresponded
uniquely to the primary amino acid sequence of PLK4 from residue
161 through 176, thus demonstrating specificity of our anti–
phospho-serine305-PLK4 antibody for PLK4 protein and pro-
viding supportive evidence that the proteins detected by this
antibody in centrosomes, kinetochores, cleavage furrow, and
midbodies are phospho-PLK4.
The observed spatial-temporal differences in subcellular dis-
tribution of phospho-PLK4 have not been reported previously
(10, 11, 22). To date, one other group has described PLK4 lo-
calization outside of centrosomes (at the central spindle) and
provided evidence for a cytokinesis defect in PLK4−/− cells (14,
15, 31). This lack of detection of the noncentrosome localiza-
tions of PLK4 is likely caused at least in part by inherent diffi-
culties in characterizing a low-abundance protein like PLK4, and
by the frequent use of antibodies targeting the carboxyl terminus
of PLK4 as well as exogenous PLK4 to overexpress the protein
and overcome these challenges (11). To address these problems,
we developed immunofluorescence techniques for localization of
PLK4 by modifying a previously described method involving the
use of sodium dodecyl sulfate (SDS) as an antigen retrieval
technique (32). This permitted localization of endogenous PLK4
in frozen tissues, probably because of the denaturing effect of
SDS on the secondary structure of PLK4 protein, or through
heat with high pH (9.0) for localization in fixed cell lines and
tissues. Our use of synchronized cells also proved to be a distinct
advantage for characterization of a protein with apparently mul-
tiple functions in different subcellular locations during different
phases of the cell cycle.
To address whether PLK4 cleavage is required for the non-
centrosome localization of PLK4, we used the inhibitor MG115,
a potent, reversible inhibitor of chymotrypsin-like and caspase-like
11310 | www.pnas.org/cgi/doi/10.1073/pnas.1818820116 Press et al.
activities, as well as calpains and various lysosomal cathepsins
(33). Short-term treatment with MG115 caused accumulation of
PLK4 in centrosomes and prevented localization of PLK4 to the
midbody (Fig. 4 A and C). After a 4-h treatment with MG115, the
number of cells with PLK4-positive centrosomes increased from
66 to 430 of 500 cells, a greater than sixfold increase (Fig. 4E). In
addition, the intensity of each individual centrosome-related signal
was substantially increased, facilitating identification (e.g., compare
“DMSO” with “MG115” in Fig. 4 A andC). In contrast, the number
of cells with PLK4-positive midbodies decreased from 59 to 20 of
500 cells, a >50% reduction after only a 4-h MG115 treatment, with
substantially less PLK4 per labeled midbody (Fig. 4 A and E). These
results strongly support the concept that activated/phosphorylated
PLK4 is cleaved into smaller fragments, perhaps removing the PB
domains that are known to bind the STIL, CEP152, and CEP192
proteins in centrosomes. This would facilitate redistribution of an
amino-terminal fragment of PLK4 to the spindle midzone/cleav-
age furrow and midbody, a distribution we have demonstrated by
colocalization of PLK4 withMKLP-1 (mitotic kinesin-like protein-1),
a known central spindle/midbody protein (Fig. 4D).
Transient Transfection with PLK4 siRNA and “Kinase-Dead” PLK4. To
confirm that PLK4 is required for duplication of centrosomes
in our models (11, 30, 34), we performed experiments using
siRNAs targeting PLK4 to down-regulate PLK4 proteins and a
PLK4-specific small molecule inhibitor to inhibit its kinase ac-
tivity. There was a >90% suppression of PLK4 mRNA following
24 h treatment with PLK4 siRNA, but no similar reduction fol-
lowing treatment with a scrambled control siRNA (SI Appendix,
Figs. S2 and S3). In contrast, as expected, there was no reduction
in PLK4 mRNA after 24 h of treatment with the PLK4 inhibitor
CFI-400945 (SI Appendix, Fig. S3A). Although the majority of
unsynchronized HCT-116 colorectal cancer cells treated with
scrambled control siRNA contained two centrosomes, indicating
that centrosome duplication occurred in the majority of cells
during this time interval, those treated with PLK4 siRNA con-
tained only one centrosome, confirming the dependency on
PLK4 for centrosome duplication in these cells (SI Appendix,
Fig. S3 B–D). Similar results were obtained with OVCAR3 hu-
man ovarian cancer cells and CAL51 human breast cancer cells
(SI Appendix, Fig. S2). These experiments also confirmed the
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Fig. 1. PLK4 is localized to centrosomes throughout S-phase, G2, and M-phase during the cell cycle when an antibody against C-terminal PB domains is used for im-
munofluorescence (IF). IF microscopy using anti-PLK4 rabbit polyclonal antibody (C-PLK4, ab137398; Abcam; to aa 614–871; red IF) and an anti–α-tubulin antibody (green
IF) in synchronized cell lines permitted identification of PLK4 in centrosomes throughout the cell cycle (interphase, prophase, metaphase, anaphase, telophase, and
cytokinesis). Results are illustrated for OVCAR3 ovarian cancer cells photographed at 400× original magnification. (Lower) Approximate location of the commercially
available (C-PLK4) antibody used for IF above. Please note differences in PLK4 distribution comparedwith Fig. 2 based on phosphorylation status and epitopes recognized.
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specificity of our anti–phospho-PLK4 antibody for protein
product encoded by the PLK4 mRNA, as described earlier (SI
Appendix, Fig. S2 C vs. D and E vs. F).
Transient transfection of HCT-116 cells with a kinase-dead
(KD) PLK4 cDNA (PLK4-K41M) sequence or a green fluores-
cence protein (GFP)-tagged wild-type PLK4 cDNA resulted in
production of tumor cells that showed centrosome amplification
with both transfectants (SI Appendix, Fig. S4). However, trans-
fectants overexpressing the PLK4-KD had predominantly mul-
tiple nuclei or multilobed nuclei, whereas wild-type PLK4
transfectants contained only single nuclei in tumor cells (SI
Appendix, Fig. S4). The presence of multiple nuclei and multi-
lobed nuclei in tumor cells transfected with KD PLK4 is con-
sistent with a role for PLK4 kinase activity in completing
cytokinesis.
Inhibition of PLK4 Kinase Activity with CFI-400945. To address
whether PLK4 kinase activity is required for completion of cytoki-
nesis, we used CFI-400945, a small-molecule inhibitor of PLK4 kinase
activity. A series of small-molecule PLK4 kinase inhibitors have
been developed and characterized during validation studies as
clinical therapeutic candidates. One of these, CFI-400945 (27–29),
is a potent and selective inhibitor of PLK4 (Ki = 0.26 nM, IC50 =
2.8 nM) relative to other PLK family members (PLK1, PLK2, and
PLK3, IC50 > 50 μM). Treatment of breast, ovarian, and colo-
rectal cancer cell lines with CFI-400945 caused a reduction in the
number of PLK4 midbody-positive tumor cells (Fig. 4 and SI
Appendix, Fig. S5), inhibition of proliferative activity (Fig. 5), and
acquisition of polyploid nuclei (Fig. 5 E and F and SI Appendix,
Fig. S5 B, D, and F). The degree of proliferative suppression in
cell culture (Fig. 5 A and B) was proportional to acquisition of
polyploid nuclei by flow cytometric analysis (Fig. 5 E and F). For
example, 21 different ovarian cancer cell lines with substantial
suppression of cell proliferation (Fig. 5B vs. Fig. 5A), as well as
24 human colorectal cancer cell lines and 32 human breast cancer
cell lines, also had the initial G0/G1 modal DNA peak shifted
almost completely from the baseline G0/G1 DNA content (Fig.
5D) to the position of the original G2/M DNA peak after 24 h
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Fig. 2. Localization of phospho-PLK4 to centrosomes, kinetochores, and midbody varies with the phase of the cell cycle when an antibody to the N-terminal
PEST domain is used. Phospho-serine305-PLK4 is identified first in centrosomes of interphase and prophase cells followed by kinetochores (metaphase and
anaphase) and, subsequently, the cleavage furrow (telophase) and midbody (cytokinesis) of synchronized cells by immunofluorescence (IF) microscopy using
an anti–phospho-serine305-PLK4 rabbit polyclonal antibody (our Ab#3 to a PLK4-serine305 peptide; red IF). Anti–α-tubulin antibody (green IF) identifies cen-
trosomes, spindle apparatus, and midbody. DAPI stain (blue) identifies DNA. Results are illustrated for OVCAR3 ovarian cancer cells photographed at 400× original
magnification. (Lower) Schematic diagram illustrates approximate location (arrows) of our rabbit polyclonal antibody (Ab#3, anti-phospho-PLK4) for phospho-
PLK4. Similar results were obtained with a second, independently produced anti–phospho-serine305-PLK4 antibody (14299) from the laboratory of G.P.N.
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treatment (Fig. 5F), demonstrating a cause-and-effect relation-
ship. The extent to which CFI-400945 treatment inhibited cell
proliferation was variable within the cell line panel. Cell lines with
only partial suppression of proliferative activity (Fig. 5A) showed
an incomplete shift in the modal DNA index from the G0/G1
DNA content to the G2/M (double) DNA content (Fig. 5 C and
E). These data are consistent with an inhibitory effect of CFI-
400945 on cytokinesis following DNA synthesis that permits a
doubling of the DNA content of individual tumor cells without
cellular abscission into two daughter cells.
To confirm this possibility through direct observation, we used
time-lapse videomicroscopy of CFI-400945 inhibitor-treated com-
pared with control cells. We demonstrated that PLK4 inhibitor-
treated cells were able to round up from the culture dish surface,
initiate, and complete M-phase with acquisition of two nuclei or
one much enlarged nucleus; however, PLK4 inhibitor-treated cells
were not able to undergo cellular abscission and therefore could
not separate into daughter cells (Movies S1–S6). Among PLK4
inhibitor-treated cells, this led to the accumulation of large cells
containing multiple nuclei or exceptionally large nuclei (Movies S2,
S4, and S6). These morphological changes contrasted with the
appearance of untreated control cells, which rapidly rounded up
from the culture surface and dissolved the nuclear envelope, with
chromosomal condensation followed by separation of chromo-
somes with formation of two separate nuclei and abscission of the
cell into two daughter cells (Movies S1, S3, and S5). In untreated
control cells, this resulted in an overall increased number of cells in
the flask, whereas PLK4 inhibitor-treated cells did not significantly
increase in number and individual cells appeared substantially
larger, with each cell having two individual nuclei or significantly
enlarged nuclei (Movies S1–S6).
Discussion
Our results suggest that PLK4, like PLK1, is involved in the
precise spatial-temporal control of cell division with sequential
localization of the protein to centrosomes, kinetochore, and
cleavage furrow/midbody facilitating microtubule organization at
centrosomes and cellular abscission at the midbody (Fig. 6). This
differs from the predominant current model that has the role of
PLK4 restricted to centrosome duplication (7, 11, 17–19, 22, 24–
26) and phosphorylation of selected proteins, such as Cdc25C
(35). Interestingly, many of the genes related to the chromosome
passenger complex (CPC) are not only localized in some of the
same subcellular organelles (kinetochore, cleavage furrow, and
midbody) during M-phase (36), but are also coexpressed with
PLK4, as are multiple members of the anaphase promoting
complex/cyclosome (APC/C). Although the ubiquitin–protea-
some pathway is the major proteolytic system in mammalian
cells, MG115 also inhibits protease activity in other cellular or-
ganelles in addition to proteasomes (33). Therefore, we can only
speculate about the cellular site of proteolytic cleavage for
PLK4, although we believe PLK4 cleavage associated with re-
distribution of phospho-PLK4 during M-phase to kinetochores,
midzone/cleavage furrow, and midbody is not likely to be asso-
ciated with the proteasome.
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Fig. 3. Western immunoblot of 19 different ovarian cell lines and one colorectal (NCI-H747) cancer cell line demonstrates full-length PLK4 (Upper Left and
Upper Right) and phospho-PLK4 (Lower Left and Lower Right). (Upper) Western blots demonstrate full-length (97-kDa) PLK4 with a commercially available
anti-PLK4 antibody (P005; Cell Signaling 3258, recognizing an epitope centered on the cysteine458 amino acid). (Lower) Western blots were performed by
using the same filter after washing with buffer and reprobing with an anti–phospho-serine305-PLK4 antibody (Ab#14299). Please note that the phospho-
PLK4 in the lower filter is of substantially smaller size, ∼60 kDa. The difference is appreciated as the full-length signals were not completely removed by
stripping in the lower filters. Cultured cells were not synchronized with regard to cell cycle. We confirmed that the 60-kDa band corresponded to pPLK4 by
removing this band from the gel and performing amino acid sequence analyses. We also confirmed that a second anti–phospho-PLK4 antibody (Ab#3) from
our laboratory recognized phospho-PLK4 by using immunoprecipitation assays followed by PAGE with silver staining to identify the band recognized on
Western blot and, finally, MS to assess the amino-acid sequence of protein band (amino-acid sequence provided in Results). SI Appendix, Fig. S1 shows results
in 23 additional colorectal and 9 breast cancer cell lines. (Lower) Schematic illustration of PLK4 amino-acid sequence shows the relative locations of epitopes
recognized by the two antibodies used for Western immunoblot analyses (Upper), one from the laboratory of G.P.N. recognizing phospho-serine305-PLK4,
produced in collaboration with Cell Signaling Technology, and the second commercially available recognizing cysteine458-PLK4.
Press et al. PNAS | June 4, 2019 | vol. 116 | no. 23 | 11313
CE
LL
BI
O
LO
G
Y
pPLK4
MKLP-1 (mitotic kinesin-like protein-1)
DNA
E
γ
Po
si
tiv
e 
PL
K
4 
st
ai
ni
ng
 p
er
 5
00
 c
el
ls
Centrosome Midbody
CFI945/MG115CFI945MG115DMSO
A
B
D
C
hours
Fig. 4. Immunofluorescence localization of PLK4 to centrosomes, cleavage furrow, and midbody is altered compared with control (A, DMSO) by treatment
with MG-115 protease inhibitor (A, MG115), CFI-400945 PLK4 kinase inhibitor (B, CFI-945), or both (B, CFI-945/MG115). Identification of PLK4 localization to
centrosomes (A, DMSO, arrow) is improved by higher magnification (C) to illustrate size difference between centrosomes (arrows) and (substantially larger)
midbodies. (D) PLK4 localization to midbodies is confirmed by colocalization with mitotic kinesin-like protein-1 (MKLP-1), a midbody protein. (E) Relative
distribution of PLK4 to centrosomes and midbodies with DMSO, MG115, CFI-945, or MG115 and CFI945 treatment. Additional descriptive details are provided
in the legend to SI Appendix, Fig. S4.
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A role in regulation of cytokinesis positions phospho-PLK4 as
a potential therapeutic target for cancer therapy. Treatment with
the CFI-400945 PLK4 inhibitor was associated with a near-
complete loss of PLK4-positive midbodies, suggesting the re-
quirement for PLK4 phosphorylation and PLK4 cleavage to fa-
cilitate migration to the cleavage furrow and midbody. Indeed,
midbodies were markedly reduced or absent in CFI-400945–
treated cells, suggesting that PLK4 plays an important role in
midbody formation and function (Fig. 6). Although centrosome
duplication is an important PLK4 function, aberrant centrosome
duplication caused by PLK4 alterations are unusual. Based on
our findings, we consider PLK4’s role in cytokinesis to be the
primary functional activity that makes PLK4 a potential target
for cancer therapeutics.
Off-target effects of the CFI-400945 PLK4 inhibitor, including
those on aurora kinase B (37), are not likely to account for the
cellular changes we observe. The biochemical 50% inhibitory
concentration (i.e., IC50) of CFI-400945 for PLK4 is 2.8 nM,
whereas, for AURKB, it is 98 nM, a 35-fold differential (38). In
addition, use of known AURKB inhibitors, such as AZD1152, in
our laboratory demonstrates divergent cellular changes when
tested in human colorectal cancer cell lines, including differen-
tial effects on cell proliferation, divergent effects in washout
assays (39), and divergent effects in outgrowth assays (39).
Interestingly, the CFI-400945 kinase inhibitor interfered with
cytokinesis in a fashion that varied among the cell lines evaluated.
Those cell lines that sustained a variable amount of proliferative
activity despite CFI-400945 treatment had a subpopulation of cells
that maintained the original modal (G0/G1) DNA index to a
variable degree. These “resistant” cell lines may represent a sub-
population of cancer cells that function as a cancer stem cell
subpopulation or a subpopulation of cancer cells with a functional
alternative pathway to facilitate cytokinesis. These studies in
multiple cell lines will be described in a subsequent report.
Cells can undergo diverse fates according to their status at
anaphase (40). Proper segregation of chromosomes in mitosis
leads to generation of two genetically identical daughter cells.
Alternatively, gradual degradation of cyclin-B in the presence of
prolonged spindle checkpoint activation causes cells to exit mi-
tosis without dividing chromosomes in anaphase, a phenomenon
termed cell “slippage” (40). Cells that exit mitosis via slippage
enter G1 as tetraploid cells and may continue to cycle, senesce,
or undergo apoptosis. Finally, anaphase catastrophe occurs when
a cell with multiple centrosomes fails to coalesce the centro-
somes into two spindle poles and enters anaphase with a multi-
polar spindle. Segregation of chromosomes to more than two
daughter cells characteristically leads to cell death. Alterna-
tively, mitotic catastrophe relates to cell death following defective
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Fig. 5. Ovarian cancer cell growth in culture with and without CFI-400945 PLK4 inhibitor: KOC-7C compared with OVCAR3. (A) Cell proliferation for KOC-7C
ovarian cancer cells without (DMSO) and with CFI-400945 PLK4 inhibitor (CFI-945) showing modest reduction in cell proliferation. N at hour 0 = 1 × 106 cells.
(B) Cell proliferation of OVCAR3 ovarian cancer cells without (DMSO) and with CFI-400945 PLK4 inhibitor (CFI-945) showing substantial inhibition of cell
proliferation. N at hour 0 = 1 × 106 cells. (C) Flow cytometry of control KOC-7C ovarian cancer cells after 24 h in culture (DMSO). (D) Flow cytometry of control
OVCAR3 ovarian cancer cells after 24 h in culture (DMSO). (E) Flow cytometry of CFI-400945 inhibitor (50 nM)-treated OVCAR3 ovarian carcinoma cells after
24 h, with large residual population of cells retaining baseline modal DNA index (blue arrow), with only partial response to inhibitor. (F) Flow cytometry of
CFI-400945 inhibitor (50 nM)-treated OVCAR3 ovarian cancer cells demonstrating no residual population of cells retaining the baseline modal DNA index (red
arrow), indicating a complete response to inhibitor. Of note, the differential response observed here is not the result of variations in the population doubling
time of the cell lines (KOC-7C = 21.00 h, OVCAR-3 = 19.49 h). Movies S1 and S2 show videomicroscopy of OVCAR3 cells with and without PLK4 CFI-
400945 inhibitor.
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cell-cycle checkpoints and the generation of aneuploid (or poly-
ploid) cells that are not able to successfully sort the complex ge-
nome into daughter cells and undergo cell death.
“Cell fate decisions” are typically made during the process of
cell division. It is hypothesized that a tumor cell reaches a critical
point at which it must “decide” between continued cell division,
apoptosis, or the capacity for stem-cell renewal. Our findings
suggest that PLK4 inhibition prevents cell proliferation and/or
induces cell death in bulk tumor cells and cancer stem cells. A
rational therapeutic approach can be based on the idea that in-
hibition of PLK4 diminishes the potential for mitotic coordina-
tion and regulation in the context of aneuploidy. We hypothesize
that, when centrosome regulation and/or the ability to complete
cytokinesis is inhibited, the balance will be tilted toward anaphase
(or mitotic) collapse and away from the potential for continued
division or the selection of the cancer stem cell renewal fate.
In addition, the PLK4 inhibitor CFI-400945 may synergize
with other drugs such as standard chemotherapeutic agents that
act on other members of a PLK4-coexpression network, regulating
the cell cycle. For example, an agent that promotes anaphase
catastrophe, such as CFI-400945, with a microtubule-targeting
drug may prove an attractive combination regimen. Taxanes
target microtubules and disrupt normal timing of mitosis by
delaying the spindle assembly checkpoint (SAC) activity. More-
over, the PLK4-coexpression network includes topoisomerase II-
alpha (TOP2A) and Mps1/TTK, both of which have drugs tar-
geting their activity and are available for combination testing
(irinotecan and CFI-401870). Inhibitors of other anaphase catastro-
phe pathways, such as CDK2 (41) (Seliciclib/CYC202/R-roscovitine)
M
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G2
No PLK4
Full Length PLK4
PLK4 C-terminal
PLK4 N-terminal
Fig. 6. Schematic diagram illustrates PLK4 distribution and functions throughout the cell cycle. The cellular images to the right illustrate changes associated
with progression through the cell cycle beginning with interphase/G1 at the extreme right. During the transition from G1 to S-phase, PLK4 is localized to the
centrosome. Subsequently, PLK4 expression, but not kinase activity, is required for centrosome duplication. PLK4 is localized to both centrosomes.
Throughout M-phase, antibodies to C-terminal PLK4 sites localize the protein continuously to both centrosomes. However, antibodies to phospho-serine305-
PLK4 localize N-terminal PLK4 first to the kinetochore (metaphase and anaphase), then to the central spindle of the cleavage furrow (telophase), and finally
to the midbody (cytokinesis), where PLK4 kinase activity is required for cellular abscission at the conclusion of M-phase. CFI-400945 treatment: the cellular
images on the left side of the schematic drawing show the changes related to treatment with the PLK4 kinase inhibitor CFI-400945, which prevents phos-
phorylation of PLK4. As a result, movement of PLK4 to the kinetochores, cleavage furrow, and midbody is inhibited; cellular abscission is prevented; and
daughter cells are not able to separate from one another, forming larger cells with polyploid nuclei or double nuclei. Adapted by permission of ref. 18,
Springer Nature: Nature Reviews Molecular Cell Biology, copyright 2014; and by permission of ref. 49, Springer Nature: Nature Cell Biology, copyright 2012.
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or Mps1/TTK (6), might be effective in combination with CFI-
400945. Preliminary results already suggest synergy between
CFI-400945 and irinotecan (TOP2A) and between CFI-400945
and CFI-401870 (TTK/MPS1).
Based on our observations, PLK4 has a regulatory role in cen-
trosome duplication and may function as an integrative protein
that localizes to different subcellular organelles including the
centrosome, kinetochore, cleavage furrow, and midbody during
different portions of the cell cycle (interphase, prophase, meta-
phase, anaphase, telophase, and cytokinesis) with catalytic activity
that can be modulated by interactions with different intracellular
inhibitors and activators in each of these locations that include a
role in cell abscission during cytokinesis.
Materials and Methods
Tissue Culture. We used breast cancer (HCC1569, HCC1954, BT549, MDA-MB-
415, HCC202, MCF7, T47D, CAL51), ovarian cancer (KOC-7C, SKOV3, HEYC2,
COLO704, RMG-1, KK, ES-2, EFO21, MCAS, A2780, OV167, PEA2, TOV-21G,
OV90, OV207, Kuramochi, OVISE, OVMANA, PEO6, CaOv-3, OV177,
OVCAR3, OVCAR5, OVSAHO, OVTOKO, PEO14), colorectal cancer (HCT-116,
HCT-15, DLD-1, COLO 205, COLO320DM, COLO320HSR, NCI-H747, NCI-
H716, COLO201, LS1034, SNU-C2B, SNU-C1, LS513, LS411N, ATR-FLOX,
LS174t, WiDr, RKO, SK-CO1, HCT-8, LS-180, HT-29, C2Bbe1, SW480), and
immortalized breast epithelial (MCF-10–2A, MCF-12A) cell lines from the
American Type Culture Collection (ATCC) or the Deutsche Sammlung von
Mikroorganismen und Zellkulturen (DSMZ) for our experiments grown as
described elsewhere (42–44). Cultured cells were synchronized as needed by
using single or double thymidine blockade. For experiments with CFI-400945,
the PLK4 inhibitor was added to medium at 10 nM, 50 nM, 100 nM, or 500 nM
concentrations and compared with results with DMSO controls.
Anti–Phospho-Serine305-PLK4 Antibody. The rabbit anti–phospho-serine305-
PLK4 antibody (Ab#3) detecting phosphorylated S305-PLK4 was produced by
a commercial vendor (Agro-Bio) with double-affinity purification of rabbit
anti-serum after immunization with synthetic peptide (SISG{pS}LFDKRRLLC)
coupled to keyhole limpet hemocyanin, as described by others (20).
Competition Studies with PLK4 Peptides. Competition studies were performed
for each rabbit anti-PLK4 antibody (ab137398; Abcam; catalog no. 3258; Cell
Signaling Technology) or anti–phospho-PLK4 antibody [our Ab#3, produced
commercially by Agro-Bio with SISG{pS}LFDKRRLLC as peptide immunogen
(20)] using different PLK4 or phospho-PLK4 peptides. The peptide used for
competition with antibody 3258 (P005) included the antigenic site of our
antibody (PLK4 Blocking Peptide, 11842S; Cell Signaling Technology) at a
concentration of 2 μg/mL (a 10-fold excess compared with the antibody
concentration). The peptide used for competition with antibody ab137398
(C-PLK4) was full-length PLK4 (P4771, recombinant PLK4 protein from
Abnova) at a concentration of 10 μg/mL (a 10-fold excess compared with the
antibody concentration). The peptide used for competition with our Ab#3,
anti–phospho-PLK4, was the peptide SISG{pS}LFDKRRLLC (courtesy of Jackie
Mason, University of Toronto, Toronto, ON, Canada) at a concentration of
10 μg/mL (a 10-fold excess compared with the antibody concentration). These
peptides were added to the diluent of the anti-PLK4 antibodies before
performing the immunofluorescence procedure on the cells.
Immunoprecipitation. Cell lysates were prepared by treating 10 million cells
with 1mL Tris-buffered saline (TBS) solution, 350mMNaCl, and 0.3%Nonidet
P-40 (FNN0021; Life Technologies) plus Protease Inhibitor Mixture (P8340;
Sigma) on ice for 30 min. The lysate was cleared by centrifuging at 16,000 × g
for 20 min at 4 °C. Immunoprecipitation of the lysates was performed with
column-based technology by using cross-linking and spin column sample-
handling (Pierce Crosslink IP Kit, no. 26147; Thermo Scientific). Rabbit
polyclonal anti–phospho-serine305-PLK4 antibody was cross-linked to pro-
tein A/G-coated agarose beads with disuccinimidyl suberate (DSS). The pre-
pared lysates were precleared by using control beads. The antibody resin
was incubated with the cell lysate overnight at 4 °C, allowing the anti-
body:antigen complex to form. The beads were washed (0.025 M Tris, 0.15 M
NaCl, 0.001 M EDTA, 1% Nonidet P-40, 5% glycerol, pH 7.4) to remove
nonbound components of the sample. The bound antigen was recovered by
dissociation from the antibody with acidic elution buffer (pH 2.8) twice. The
procedure was performed in a microcentrifuge spin cup, allowing eluted
solutions to be fully separated from the agarose resin by centrifugation.
Only antigen is eluted by the procedure, facilitating protein identification
with subsequent MS without interference from antibody fragments.
SDS/PAGE and Silver Staining of Gel. Eluted protein from immunoprecipita-
tion and column chromatography was separated by electrophoresis on
polyacrylamide gels at 100 V for 90 min or until the samples were sufficiently
separated. The gel was rinsed in water, fixed for 30 min (methanol and acetic
acid solution), washed twice for 20 min each (400 mL deionized distilled
water), and stained for 20 min by using a commercially available silver
staining solution (NH4NO3 and AgNO3; silver stain plus, 161–0449; Bio-Rad).
Staining was stopped with 5% acetic acid (15 min) followed by washing with
deionized distilled water (5 min). The silver-stained bands of interest were
identified by a Western immunoblot processed in parallel to identify bands
recognized by rabbit polyclonal anti–phospho-serine305-PLK4. The identi-
fied bands were excised from the gel and processed as described as follows.
Digestion of Immunoprecipitates Separated by SDS/PAGE and MS. After re-
duction and alkylation using dithiothreitol (DTT) and iodoacetamide (IAA),
excised gel bands were digested into peptides by using trypsin. The resulting
peptides were acidified, desalted using a Sep-Pak C18 column, and then
subjected to liquid chromatography (LC)–MS/MS sequencing and data
analysis. The identification of released PLK4 interaction was carried out by
an LC/MS system consisting of an Eksigent NanoLC Ultra 2D and Thermo
Fisher Scientific LTQ Orbitrap XL. Proteome Discoverer 1.3 (Thermo Fisher
Scientific) was used for protein identification by using Sequest algorithms.
The following criteria were followed. The variable modifications used were
carbamidomethylation (C) and oxidation (M). Searches were conducted
against UniProt or an in-house customer database. We also validated the
identifications by manual inspection of the mass spectra (45).
Western Immunoblot. Western immunoblot analyses were performed as de-
scribed previously (46) using antibodies recognizing PLK4 (3258; Cell Sig-
naling Technology and Abcam), phospho-PLK4 (Ab#3 and 14299), γ-tubulin
(clone GTU-88; Sigma), and α-tubulin (DM1A mouse monoclonal antibody
T6199; Sigma).
Immunofluorescence. The subcellular localization of various proteins was
performed with immunofluorescence using antibodies recognizing PLK4
(3258; Cell Signaling Technology and Abcam), phospho-PLK4 (Ab#3 and
14299; Agro-Bio and Cell Signaling), γ-tubulin, α-tubulin, kinetochores, and
mitotic kinesin-like protein-1 (MKLP1; mouse monoclonal sc-390113; Santa
Cruz Biotechnology). An SDS antigen retrieval technique (32) was used with
frozen or fresh cells, whereas heat-induced antigen retrieval with high pH
(9.0) was used with fixed, paraffin-embedded cell lines.
Proliferation Assays. Proliferation assays were performed by using 2 × 105 cells
per T75 flask over an 8-d period according to standard protocols (47).
Flow Cytometry. Analyses of DNA content and cell cycle were performed with
flow cytometry (48).
PLK4 siRNA Knockdown. Depletion of PLK4 was performed by using Trilencer-
27 siRNA duplexes against PLK4 (SR307314; OriGene) at a final concentration
of 20 nM with Universal scrambled negative control siRNA duplex (SR30004;
OriGene) as control. Transfections were performed by using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s forward transfection
protocol. Briefly, 240 pmol of siRNA and 54 μL of Lipofectamine RNAiMAX
were used to prepare RNAi duplex-Lipofectamine RNAiMAX complexes in
1,800 μL of Opti-MEM I medium (Invitrogen). Cells were cultured in T-75
flasks until 50% confluence was achieved before treatment. Cells were
collected 24–96 h after transfection for real-time PCR analysis and immu-
nofluorescent staining to monitor PLK4 knockdown.
Transient Transfection Assays. Transient transfections were performed with
FuGENE HD Transfection Reagent according to the manufacturer’s recom-
mendations (Promega). Briefly, one part of PLK4-WT or PLK4-KD plasmid
DNA was combined with three parts of FuGENE HD Transfection Reagent
and incubated for 15 min at room temperature. Ten microliters of the
FuGENE HD Transfection Reagent/DNA mixture were added to each well of
12-well plates containing 10,000 cells per well in 600 μL growth medium. The
cells were cultured for 24–48 h and assayed 24–48 h after transfection.
Time-Lapse Videomicroscopy. A Zeiss inverted, spinning confocal microscope
containing a stage-top incubator was used to perform time-lapse video
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microscopy. HCT116 or OVCAR3 cells were seeded in growth medium in Glass
Bottom Microwell Dishes (MatTek). After attaching to the glass surface for
24 h, the cells were synchronizedwith a thymidine block for 12–16 h. The cells
were then released into fresh medium containing 50 nM CFI-400945 or the
same quantity of DMSO before being positioned on the stage. The same
protocol was adhered to when preparing CAL51 cells for acquisition but by
using MatTekII four-well chamber slides.
Time-lapse video microscopy of the HCT116 and OVCAR3 cells was per-
formed with a cell observer (Zeiss) at constant conditions of 37 °C and 5%
CO2. Phase-contrast images were acquired every minute for 18 h by using a
10× phase-contrast objective (Zeiss) and an AxioCam HRm camera with Zeiss
AxioVision 4.7 software. Time-lapse video microscopy of the CAL51 cells was
performed with an AxioObserver (Zeiss) at constant conditions of 37 °C and
5% CO2. Differential interference contrast (DIC) microscopic images were
acquired every minute for 22.15 h by using a 20× objective and an Axiocam
506 camera with Zeiss Zen Pro software.
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